Jonsson Comprehensive Cancer Center clinical trial pipeline

6 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 3 with minor changes only.

1. Notable

   Talazoparib and Low-Dose Temozolomide · Relapsed or Refractory…Talazoparib and Low-Dose Temozolomide · Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

   Primary completion pushed from Oct 1, 2026 to Oct 1, 2027

   Also in this update: Study completion pushed from Oct 1, 2027 to Oct 1, 2028

   Jonsson Comprehensive Cancer Center·Phase 2· NCT03672773· Registry history of NCT03672773 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

2. Notable

   Germ-Line Mutations in Blood and Saliva Samples From · Cancer

   Primary completion pushed from Sep 16, 2026 to Sep 16, 2027

   Also in this update: Study completion pushed from Sep 16, 2027 to Sep 16, 2028

   Jonsson Comprehensive Cancer Center·Not specified· NCT02280161· Registry history of NCT02280161 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

3. Notable

   STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck…STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

   Primary completion pushed from Sep 2, 2031 to Sep 2, 2032

   Also in this update: Study completion pushed from Apr 21, 2032 to Sep 2, 2033

   Jonsson Comprehensive Cancer Center·Not applicable· NCT07612293· Registry history of NCT07612293 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.